Venus Remedies has achieved market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/lnfusion by its German subsidiary, Venus Pharma GmbH. This remarkable milestone not only expands the pharma giant's global presence but also underscores its commitment to advancing cancer care with innovative solutions.
Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulfate. It belongs to a group of medicines known as cytostatjc drugs, specifically designed to combat cancer. This class of medications, often referred to as chemotherapy, is renowned for its effectiveness in targeting cancer cells and preventing their uncontrolled division.
Its versatile applications include the treatment of certain types of squamous cell carcinomas in the head and neck, cervix and external genitalia. It also serves as a panacea in treating severe types of lymph node cancers, such as Hodgkin's disease and nan-Hodgkin's lymphoma of intermediate and high malignancy, testicular cancer, and fluid accumulation in the lungs, often associated with cancer.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |